Evoke Pharma Total Non-Operating Income/Expense 2012-2024 | EVOK

Evoke Pharma total non-operating income/expense from 2012 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
Evoke Pharma Annual Total Non-Operating Income/Expense
(Millions of US $)
2023 $-0
2022 $-0
2021 $-0
2020 $-0
2019 $0
2018 $0
2017 $-1
2016 $-0
2015 $-0
2014 $-0
2013 $-0
2012 $-0
2011 $0
Evoke Pharma Quarterly Total Non-Operating Income/Expense
(Millions of US $)
2024-09-30 $-0
2024-06-30 $-0
2024-03-31 $-0
2023-12-31 $-0
2023-09-30 $-0
2023-06-30 $-0
2023-03-31 $-0
2022-12-31 $-0
2022-09-30 $-0
2022-06-30 $-0
2022-03-31 $-0
2021-12-31 $-0
2021-09-30 $-0
2021-06-30 $-0
2021-03-31 $-0
2020-12-31 $-0
2020-09-30 $-0
2020-06-30 $-0
2020-03-31 $0
2019-12-31 $0
2019-09-30 $0
2019-06-30 $0
2019-03-31 $0
2018-12-31 $0
2018-09-30 $0
2018-06-30 $0
2018-03-31 $0
2017-12-31 $2
2017-09-30 $-2
2017-06-30 $1
2017-03-31 $-3
2016-12-31 $1
2016-09-30 $-1
2016-06-30 $-0
2016-03-31 $-0
2015-12-31 $-0
2015-09-30 $-0
2015-06-30 $-0
2015-03-31 $-0
2014-12-31 $-0
2014-09-30 $-0
2014-06-30 $-0
2014-03-31 $-0
2013-12-31 $-0
2013-09-30 $0
2013-06-30 $-0
2013-03-31 $-0
2012-12-31
2012-09-30 $-0
2012-06-30
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.007B $0.005B
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Teligent (TLGT) United States $0.000B 0.00